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Abstract
Background: It is well known that familial sick sinus syndrome (SSS) is caused by functional alterations of ion channels and
gap junction. Limited information is available on the mechanism of age-related non-familial SSS. Although evidence shows a
close link between arrhythmia and the renin-angiotensin system (RAS), it remains to be determined whether the RAS is
involved in the pathogenesis of non-familial SSS.
Methods: In this study, 113 patients with documented non-familial SSS and 125 controls were screened for
angiotensinogen (AGT) and gap junction protein-connexin 40 (Cx40) promoter polymorphisms by gene sequencing,
followed by an association study. A luciferase assay was used to determine the transcriptional activity of the promoter
polymorphism. The interaction between nuclear factors and the promoter polymorphism was characterized by an
electrophoretic mobility shift assay (EMSA).
Results: Association study showed the Cx40 -44/+71 polymorphisms are not associated with non-familial SSS; however, it
indicated that four polymorphic sites at positions -6, -20, -152, and -217 in the AGT promoter are linked to non-familial SSS.
Compared to controls, SSS patients had a lower frequency of the G-6A AA genotype (OR 2.88, 95% CI 1.58–5.22, P=0.001)
and a higher frequency of the G allele at -6 position (OR 2.65, 95% CI 1.54–4.57, P=0.0003). EMSA and luciferase assays
confirmed that nucleotide G at position -6 modulates the binding affinity with nuclear factors and yields a lower
transcriptional activity than nucleotide A (P,0.01).
Conclusion: G-6A polymorphism, which modulates the transcriptional activity of the AGT promoter, may contribute to non-
familial SSS susceptibility.
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Introduction
Sick sinus syndrome (SSS), including profound sinus bradycar-
dia, sinus arrest, sino-atrial exit block, and tachy-bradycardia, is a
group of abnormal heart rhythms presumably caused by a
malfunction of the sinus node [1,2]. The syndrome is prevalent
in 1 out of every 600 individuals over the age of 65 years, and
accounts for approximately 50% of pacemaker implantations
[1,2]. Growing evidence has shown that genetic mutations in the
hyperpolarization-activated cyclic nucleotide-gated cation channel
(HCN-4), the cardiac sodium channel (SCN5A), and gap junction
protein (connexin) may lead to familial SSS [3–5]. In contrast to
the progress in illustrating the mechanism for familial SSS, limited
information is available regarding the mechanism of age-related
non-familial SSS [6,7].
Gap junctions composed of connexin (Cx) molecules are
responsible for the electrical coupling of cardiac myocytes. In the
human heart, there are 3 cardiac connexinisotypes,Cx40,Cx43and
Cx45. Cx40 is the major isotype expressed in the atrium. In Cx40
knockout mice, increased atrial vulnerability has been shown to cause
arrhythmogenesis [8]. In addition, Cx40 promoter polymorphism
has been linked to congenital atrial standstill and atrial arrhythmia
[4,9]. However, it is still unclear whether alterations in gap junction
proteins would contribute to non-familial SSS.
It is generally accepted that the renin-angiotensin system (RAS)
can modulate the functions of the sinus node and cardiac
conduction system [10–12]. Angiotensin II is known to induce
cardiac fibrosis and myocardial hypertrophy through angiotensin
II type I (AT1) receptors [13]. A study using transgenic mice
demonstrated that overexpression of the AT1 receptor in the
myocardium, which was lethal, was associated with myocyte
hyperplasia, heart block, and sinus bradycardia [14]. However, the
role of RAS in the pathogenesis of age-related non-familial SSS
remains to be determined.
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(AGT) promoter polymorphism and stroke have indicated that
polymorphic alterations of the AGT promoter modulate its
transcriptional activity and cause cerebral vascular diseases
[15,16]. In addition, a study using AGT knockout mice showed
a feedback mechanism for regulating the expression of RAS
molecules and the AT1 receptor [17]. Thus, we hypothesized that
AGT promoter polymorphism modulates the expression of RAS
molecules and thereby influences sinus node function. Here, the
data reported indicates a possible relationship between age-related
non-familial SSS and the AGT promoter polymorphism. Appar-
ently, polymorphic variations in the AGT promoter might
contribute to non-familial SSS susceptibility by modulating the
activity of RAS in patients.
Methods
Ethics statement
The study protocol was approved by the Institutional Review
Board of China Medical University Hospital. Written informed
consent was obtained from each participant or each participant’s
guardian after a full explanation of the study. The investigation
conformed with the principles outlined in the Declaration of
Helsinki.
Study population
A total of 113 consecutively eligible patients with documented
SSS were studied. SSS was diagnosed by symptomatic bradycardia
with evidence of sinus node dysfunction. The criteria for inclusion
were symptomatic bradycardia with a documented sinus pause of
greater than 3 seconds or sinus bradycardia of less than 40 beats/
min for more than 1 min while awake [18,19]. Other supporting
evidences were provided by a cardiac electrophysiologic study to
determine the prolonged corrected sinus nodal recovery time.
Long sinus pauses and profound sinus bradycardia were also
examined by using a series of electrocardiograms (ECG) and
ambulatory ECG. All SSS patients met the indications for
permanent pacemaker implantation. Patients with a history of
familial SSS, severe systemic disease, acute coronary syndrome,
neurogenic or drug-induced bradycardia, or bradycardia with
reversible cause were excluded from this study. The control group
consisted of 125 age- and sex-matched unrelated volunteer
patients who were free of SSS and underwent clinical follow-up
in the cardiovascular outpatient department of the same hospital.
Genotyping and association study
Blood samples from patients were prepared, and genomic DNA
was isolated using a DNA extraction kit (Illustra
TM,G E
Healthcare). Polymerase chain reactions (PCRs) were performed
with 100 ng genomic DNA, 2–6 pmol of selected primers, 1X Taq
polymerase buffer, and 0.25 units of AmpliTaq Gold
TM
polymerase (Roche) in a final reaction volume of 50 mL using a
programmable thermal cycle (GeneAmp PCR system 2700,
Applied Biosystems, CA). The primers for the AGT promoter
were 59-CCTCTTGGGGGTACATCTCC-39 (forward) and 59-
TCCTAGCCCACAGCTCAGTT-39 (reverse). The primers for
the Cx40 promoter were 59-AGGCTACGAGGAGGTGGA-39
(forward) and 59-AACTCACAGGTAGAAAGAAAGAGC-39 (re-
verse). The gene sequences of the PCR products were subse-
quently determined by using a gene sequencing analyzer (ABI
3730 XL DNA Analyzer, Applied Biosystems). An association
study between gene promoter polymorphisms and SSS was
performed to measure the frequency of the genotypes and alleles
of the Cx40 and AGT promoters in SSS and control groups.
Construction of expression vectors, transfection, and
luciferase activity measurement
The association study showed that polymorphic sites in the
AGT promoter were located within the proximal region of the
promoter. Therefore, this region (position 2290 to +35 relative to
transcription starting site) was amplified by PCR from the genomic
DNA of homozygous patients. Primers to amplify AGT polymor-
phisms were designed to contain the restriction sites of MluI and
BglII (for cloning) and polymorphic sites for AGT promoter:
forward primer, 59- ACCGACGCGTAGATGCTCCCGTTT-
CTGG -39 (artificial MluI restriction site underlined); reverse
primer, 59-CGGAAGATCTTCTGCTGTAGTACCCA-39 (arti-
ficial BglII restriction site underlined) (Figure 1). After digestion
with MluI and BglII, PCR products were ligated into the
corresponding restriction sites of the pGL3 plasmid containing
the luciferase reporter gene according to the manufacturer’s
instructions (Promega). The promoter-luciferase constructs con-
taining the -6G and -6A polymorphic sites are defined as P(-6G)
and P(-6A), respectively.
The constructs were transiently transfected into HepG2 (cell
line-derived from human hepatoma; HB-8065; ATCC) and
cultured in Dulbecco’s Modified Eagle Medium (DMEM) without
serum using a transient liposome (Lipofetamine2000; Invitrogen,
Carlsbad, CA) cotransfection method. A control vector containing
the beta-galactosidase gene (Promega; 0.2 mg) was used as an
internal control of transfection. Luciferase assays were performed
using the Dual-Light Luciferase Assay System (PerkinElmer).
Electrophoretic mobility shift assay
Electrophoretic mobility shift assays (EMSA) were performed by
using the EMSA ‘‘Gel Shift’’ Kit (Panomics, Fremont, CA, USA).
To determine the essential role of the specific position at -6 at the
proximal segment of the AGT promoter, 2 different lengths of
oligonucleotides containing the nucleotide A or G at -6 of the
AGT promoter were designed for the longer oligonucleotide, G33
or A33, and for the shorter oligonucleotide, G23 or A23. The
sequences for these double-stranded oligonucleotides are listed
below with the polymorphic sites underlined:
G23:59-GTGACCCGGCCGGGGGAAGAAGC-39, A23:59-
GTGACCCGGCCAGGGGAAGAAGC-39, G33:59-AAATAG-
GGCATCGTGACCCGGCCGGGGGAAGAA-39, A33:59-AA-
ATAGGGCATCGTGACCCGGCCAGGGGAAGAA-39.
These synthesized oligonucleotides were labeled with biotin at
the 39 end. The biotinylated oligonucleotide (10 ng/mL) was added
to nuclear extracts of HepG2 cells after their nuclear proteins were
incubated with poly (dI-dC) (1 mg/mL) and binding buffer for
5 minutes. The specific binding was evidenced by adding a 50- to
100-fold excess of corresponding non-labeled oligonucleotide with
nuclear extracts prior to the addition of the biotinylated probe for
each sample preparation. Binding reaction mixtures were then
incubated for 30 min at 15uC. After electrophoresis, gels were
transferred to nylon membranes. For detection of bound
oligonucleotides, membranes were blocked using blocking buffers
(Panomics EMSA Gel-Shift Kit) followed by the addition of
Streptavidin-HRP, and blots were developed by ECL according to
the manufacturer’s instructions.
Resting ECG recordings
The patients resting in supine position for 10 minutes were
performed ECG recordings. Both heart rate and PR interval were
taken into account as essential factors affecting sinus node function
and rhythmic conduction in the heart [1]. The control patients
without SSS were divided into two groups with age and sex match
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fibrillation or without ability to maintain sinus rhythm during
ECG recording were excluded.
Holter ECG
A Holter ECG monitor is a portable recorder that can
continuously record the heart rate and rhythm for at least
24 hours [20]. In the present study, Holter ECG monitoring was
performed for 24 hours for those patients who required monitor-
ing for a longer period to evaluate their heart rhythm or to provide
supporting evidence for the diagnosis of rhythm disorders.
Electrophysiologic study
An electrophysiologic study is an invasive tool that can evaluate
sinus node function and the conduction system [21]. An
electrophysiologic study can provide supporting evidence for the
diagnosis of SSS or further evaluation of bradycardia. Some
patients with non-familial SSS can be diagnosed by series ECG,
bedside ECG mornitoring, ECG telemetry monitoring and
concurrent symptoms and/or signs of bradycardia [1,18,19].
Therefore, an electrophysiologic study was not performed for part
of patients with non-familial SSS. All patients in the control group
are free of symptoms and signs of non-familial SSS based on
careful history taking, resting ECG and heart rate follow-up.
Therefore, an invasive electrophysiologic study was not performed
for the control group due to ethic issue. The invasive electrophys-
iologic study was performed when bradycardia occurred inciden-
tally and could not be well evaluated by non-invasive methods or
when a serious underlying mechanism for bradycardia was
suspected [21]. The phenomenon of post-pacing depression of
the sinus node was utilized to evaluate the sinus node function for
the study subjects by analyzing the sinus node recovery time (SRT)
as described in a previous report [22]. The SRT is defined as the
interval between the last paced P wave and the following sinus P
wave. The corrected SRT (CSRT) is defined as the recovery
interval in excess of the sinus cycle (SRT -sinus cycle length). The
SRT was measured following overdrive suppression for sinus node
by right atrial pacing at rates of 100 to 150 beats/min for
2 minutes at each pacing rate. A CSRT longer than 525 ms is
considered prolonged [22].
Statistical analysis
Student’s t test was used when the continuous data were
normally distributed; otherwise, the nonparametric Mann-Whit-
ney U test was used. Categorical data were compared by the
conventional chi-square test if the observation numbers in all
categories were larger than 5; otherwise, the Fisher exact test was
used. Numeric variables for the promoter genotypes were
compared using one-way analysis of variance (ANOVA). For each
polymorphism, the genotype proportions with Hardy–Weinberg
equilibrium (HWE) were assessed by using the conventional x
2
goodness-of-fit test. Haplotype profile analysis for the polymor-
phisms was estimated by using Haploview software [23]. Owing to
short distances between each polymorphism location on the AGT
gene, polymorphisms probably did not separate by recombination
and had linkage disequilibrium (LD) [24]. Thus, pairwise
measurement of LD was performed to test the LD between the
polymorphisms. D’ was used to estimate LD. Because the
magnitude of D’ strongly depends on the sample size, and it is
known to increase when a small number of samples or rare alleles
are examined, we also utilized the r
2 value to confirm LD.
Expectation-maximization (EM) based haplotype frequency esti-
mation with a permutation test was performed to determine
whether any specific haplotypes are associated with SSS on the
basis of previous reports [24–26]. Statistical significance of LD was
defined as r
2.1/3 and D9.0.7, as suggested by previous reports
Figure 1. Construction of expression variants in pGL3 vector using oligonucleotides for the proximal AGT promoter. The
oligonucleotides containing the proximal promoter region of the AGT gene from position 2290 to +35 were ligated in the pGL3 vector to produce
the reporter construct. luc+ = cDNA encoding the modified firefly luciferase; Amp
r = gene conferring ampicillin resistance; f1 ori = origin of
replication derived from filamentous phage; E = exon.
doi:10.1371/journal.pone.0029951.g001
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Results
Patient characteristics
The clinical features of SSS patients and controls are
summarized in Table 1. There were no significant differences in
age, gender, percentage of patients with hypertension, diabetes
mellitus (DM), coronary artery disease (CAD), atrial fibrillation
(AF), and left ventricle dysfunction between groups.
HWE tests and LD measurements
Four polymorphic sites were found at positions -6, -20, -152,
and -217 within the promoter region of the AGT gene (Figure 2
and Figure S1, S2, and S3). The HWE genotype distributions were
assessed for each AGT promoter polymorphism G-6A, A-20C, G-
152A, and G-217A by the conventional chi-squared goodness-of-
fit test. The P-value was 0.33, 0.65, 0.47, and 0.29, respectively. In
addition, the same test was also performed for the SSS and control
groups separately. The AGT genotype distribution in the SSS and
control groups did not significantly deviate from the HWE (P.0.2
in each polymorphism).
The pairwise linkage among these four polymorphic sites on the
AGT promoter gene was evaluated by the LD test using D’ and r
2.
The D’ values of the loci pairs for -6/-20, -6/-152, -6/-217, -20/
-152, -20/-217, and -152/-217 were 1, 1, 1, 1, 0.463, and 0.699,
respectively. The corresponding values for r
2 were 0.028, 0.008,
0.039, 0.277, 0.005, and 0.001, respectively (Figure 3). The D’
values indicated a significant linkage in the loci pairs of -6/-20,
-6/-152, -6/-217 and -20/-152. However, the r
2 values for these
three loci pairs were low. This inconsistency between the D’ and r
2
values may be due to the small sample size in this study [26]. The
high D’ values and the low r
2 values of these 4 loci pairs (-6/-20,
-6/-152, -6/-217 and -20/-152) suggest an incomplete linkage
among these 4 loci pairs, which explains the wide range of
haplotypes for the AGT gene.
Two polymorphic sites were found at position of -44 and +71 in
Cx40 gene (Figure S4). The Cx40 genotype distribution in total
population, SSS patients and control groups did not significantly
deviate from the HWE (P=0.46, 0.38 and 0.65, respectively).
These two Cx40 polymorphisms were in complete linkage
disequilibrium. The patients with allele G at position -44,
consistently had A at -71 position and vice versa.
Relationship between the AGT promoter haplotypes and
SSS
In the present study, five major haplotypes in the AGT
promoter showing a frequency of .0.01 were identified, and their
relationship with SSS was examined. The GGAG haplotype
(-217G, -152G, -20A, -6G) occurred with a significantly higher
frequency in the SSS group compared to the control group
(haplotype frequency: 0.2035 vs. 0.0880; OR=2.65, P=0.0003;
Table 2).
Single locus analysis of AGT promoter polymorphisms
and SSS association
A significant difference was observed in the distribution of the
genotypes at position -6 between SSS and control subjects
(P=0.001). The AA genotype frequency of G-6A was significantly
lower in the SSS group than in the control group (OR=2.88, 95%
CI: 1.58–5.22, P=0.001). The G allele frequency of G-6A was
significantly higher in the SSS group than in the control group
(20.4% vs. 8.8%, OR=2.65, 95% CI: 1.54–4.57, P=0.0003)
(Table 3). Results of the haplotype analysis and single locus
analysis indicate a significant association between G-6A polymor-
phism and SSS.
Genotypes and alleles distribution of Cx40
polymorphisms in SSS patients and controls
Owing to the Cx40 polymorphisms at positions -44 and +71
were in complete linkage disequilibrium, we only reported the
results for Cx40 -44(GA) polymorphism. There was no significant
difference in the distribution of allele frequency of -44G and -44A
and genotype distribution of -44AA, -44AG and -44GG between
SSS and control patients (P=0.50 and 0.77, respectively). These
results indicate no association between Cx40 -44 polymorphism
and non-familial SSS (Table 3).
Transcriptional activity of the various AGT promoter
polymorphisms
The effect of polymorphisms on AGT promoter activity was
determined by transiently transfecting plasmids containing AGT
promoter polymorphisms upstream of the luciferase gene into a
hepatocyte (HepG2) cell line and measuring luciferase activity.
The AGT promoter containing G at -6 (p(-6G)) had a lower
transcriptional activity than the AGT promoter containing A at -6
(p(-6A)) in HepG2 cells ( P,0.05) (Fig. 4). This suggests that
decreased AGT promoter activity in RAS is involved in the
pathogenesis of SSS.
In the transcription activity study using the luciferase assay, we
found that the AGT promoter containing G at -6 had a lower
transcriptional activity than the AGT promoter containing A at -6.
According to the transcriptional activity study by luciferase assay,
we identified the homozygous AA genotype as the genotype with
the highest transcription activity, the heterozygous AG genotype as
the genotype with an intermediate transcriptional activity and the
homozygous GG genotype as the genotype with the lowest
transcription activity. Accordingly, the control group had a higher
frequency of genotype with the highest transcription activity than
Table 1. General characteristics of patients included in the
study.
SSS Control
(N=113) (N=125)
Age (years) 68.9610.7 69.0.568.7 0.493
**
Gender (male/female) 37/76 46/79 0.586
1
BW (kg) 60.669.88 62.269.0 0.181
*
Height (cm) 157.867.9 158.267.9 0.761
**
HT (n, %) 41 (36.3%) 55 (44.0%) 0.226
1
DM (n, %) 28 (24.8%) 23 (18.4%) 0.231
1
CAD (n, %) 12 (10.6%) 15 (12.0%) 0.737
1
AF (n, %) 23 (20.4%) 22 (17.6%) 0.622
1
LAD (mm) 36.366.2 36.166.5 0.627
**
LVIDd (mm) 49.065.4 48.666.67 0.472
**
LVEF (%) 71.4610.7 71.3612.7 0.616
*
*Student t test; **Mann-Whitney U test;
1x
2 test; SSS = sick sinus syndrome; HT
= hypertension; DM = diabetes mellitus; CAD = coronary artery disease; LAD
= left atrial dimmesion; LVIDd = left ventricular end diastolic dimension; LVEF
= left ventriclar ejection fraction.
doi:10.1371/journal.pone.0029951.t001
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vs. 70/113(61.0%), P,0.001). In contrast to the control group, the
SSS-group possessed a higher frequency of genotypes with
intermediate or the lowest transcriptional activity (SSS group vs.
control group =43/113 (38.1%) vs. 22/125 (17.6%), p,0.001).
These results indicate the G-6A polymorphism modulates the
transcriptional activity of the AGT promoter and may contribute
to non-familial SSS susceptibility.
EMSA
The luciferase assay showing that the AGT transcription rate is
modulated by the nucleotide substitution at position -6 of the
proximal promoter reflects that polymorphic substitution of
nucleotide -6 may alter the interaction between transcriptional
factors and the proximal region of the AGT promoter,
subsequently altering the transcription rate. To test this possibility,
the direct binding experiment of EMSA was conducted to
compare the formation of retarded complexes of oligonucleotide
G33 or A33 with nuclear extracts from HepG2 cells. The results
that were obtained showed that a stronger blot shift by nuclear
proteins was observed for the biotin-labeled oligonucleotide G33
than for oligonucleotide A33. This retarded complex could be
abolished by pretreatment of each sample preparation with each
unlabeled corresponding oligonucleotide. Similarly, by adding a
shorter biotin-labeled oligonucleotide (G23 or A23), a stronger
blot shift by nuclear proteins was also observed for G23 than for
A23 (Figure 5).
Effects of AGT G-6A and Cx40 -44/+71 polymorphisms on
heart rate and PR interval in control patients without SSS
To verify the functional association of G-6A polymorphism to
non-familial SSS, we examined whether ATG G-6A polymor-
phism in control patients without SSS would affect their sinus
node function. Both heart rate and PR interval were considered as
critical factors in association with sinus node function and
rhythmic conduction of the heart. The resting heart rate in the
subjects with AG genotype is significant lower than the subjects
with AA genotype (AG vs. AA=68.2612.2 vs. 74.4611.9 beats/
min, P=0.03) (Table 4). This suggests that AGT G-6A
polymorphism might play a role in sinus rate control. In addition,
the subjects with AG genotype also showed a trend of longer PR
interval than the subjects with AA genotype (AG vs,
AA=164.9626.5 vs. 154.1618.2 ms, P=0.07) (Table 4). Con-
sistently, the control patients with AG genotype have longer
electrical conduction for the atria to ventricles that might lead to
impaired atrioventricular conduction. Thus, these results suggest-
ed that the AGT G-6A polymorphism not only associates with
non-familial SSS, but also has effects on the sinus node function in
the control subjects. In contrast to the effect of AGT G-6A
polymorphism on sinus node function, there were no significant
differences in the resting heart rate among the subjects with
different genotypes of the Cx40 -44/+71 polymorphism (AA
(n=14): AG (n=55): GG (n=50) =71.3618.2 : 73.7611.2:
73.3611.4 beats/min, P=0.70). There were also no significant
differences in the PR intervals among the patients with the
different genotypes of the Cx 40 -44/+71 polymorphism (AA: AG:
GG=156.8617.2: 157.39628.5: 154.5623.2 ms, P=0.38).
These results indicate that the Cx40 -44/+71 polymorphisms
had no effect on the sinus node function in the control subjects.
In additional to providing supporting evidence for diagnosis of
non-familial SSS, 30 subjects of the control group were evaluated
by Holter ECG monitoring for their heart rhythms. In the 30
subjects, the results showed a significant trend of a lower average
heart rate with the AG genotype (n =10) than the AA genotype
(n=20) (AG vs. AA=69.767.0 vs. 76.1611.9 beats/min,
Figure 2. AGT G-6A polymorphism genotyping by direct sequencing. The arrows indicate the polymorphic site of GG, AA and AG
genotypes.
doi:10.1371/journal.pone.0029951.g002
Figure 3. Linkage disequilibrium plot of AGT promoter
polymorphisms. Pairwise linkage disequilibrium analysis shows r
2
(6100) values. The intensity of gray is proportional to r
2.
doi:10.1371/journal.pone.0029951.g003
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significant status, they are consistent with the result of sinus rate
comparison by resting ECG in the control group. These results
support the findings that the AGT G-6A polymorphism affects
sinus node function in the control subjects. In contrast to the effect
of G-6A polymorphism on average heart rate found by Holter
ECG, there were no significant differences in the average heart
rate among the subjects with the different genotypes of the
Cx40 -44/+71polymorphism(AA(n=14):AG(n=55):GG(n=50)
=71.0612.4 : 75.7611.7: 72.669.6 beats/min, P=0.66). These
results indicate that the Cx40 -44/+71 polymorphisms have no
effect on the sinus node function in the control subjects.
Electrophysiologic study and the genotypes of AGT G-6A
polymorphism
An electrophysiologic study has been performed for 55 non-
familial SSS patients (35 patients with the AA genotype, 18 patients
with the AG genotype and 2 patients with the GG genotype). The
CSRT was recorded in these 55 patients. There were no significant
differences in CSRT among the AGT G-6A AA, AG and GG
Table 3. Distribution of genotypes and alleles of Cx40 and AGT in patients with and without sick sinus syndrome.
Gene polymorphism Genotypes and Alleles SSS patients Control patients P
(N=113) (N=125)
Cx40 gene
G-44A AA 10 14
AG 52 59
GG 51 52 0.77
A:G 31.9%:68.1% 34.2%:65.8% 0.50
AGT gene
G-6A AA 70 103
AG 40 22
GG 3 0 0.001
A:G 79.6% : 20.4% 91.2% : 8.8% 0.0003
A-20C AA 85 89
AC 26 34
CC 2 2 0.83
A:C 86.7% : 13.3% 84.8% : 15.2% 0.55
G-152A AA 0 0
AG 12 9
GG 101 116 0.37
A:G 5.3% : 94.7% 3.6% : 96.4% 0.36
G-217A AA 3 3
AG 32 46
GG 78 76 0.39
A:G 16.8% : 83.2% 20.8% : 79.2% 0.27
SSS = sick sinus syndrome. P values obtained based on x
2 test or Fisher’s exact test; the upper P value is for comparison of genotype frequencies, and the lower is for
allele frequencies.
doi:10.1371/journal.pone.0029951.t003
Table 2. Haplotype frequency estimates of AGT gene in patients with sick sinus syndrome and controls.
Haplotype
Overall SSS Controls
-217 -152 -20 -6 (N=238) (N=113) (N=125) OR P
G G A A 0.536 0.5097 0.5600 0.82 0.2719
G G A G 0.143 0.2035 0.0880 2.65 0.0003
G G C A 0.090 0.0686 0.1096 0.60 0.1158
A G A A 0.178 0.1540 0.2000 0.73 0.1905
G A C A 0.042 0.0504 0.0344 1.49 0.3859
*There results were confirmed by permutation test which also revealed that GGAG is the only significant candidate haplotype (P=0.0007). Haplotypes are not listed if all
the estimated frequencies are ,0.01 in patients with sick sinus syndrome, controls, and overall population.
doi:10.1371/journal.pone.0029951.t002
AGT Gene Polymorphism and Non-Familial SSS
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29951Figure 4. Comparison of the transcriptional activities of reporter constructs containing AGT proximal promoter polymorphisms in
HepG2 cells. Transcriptional activities are presented as a ratio of the activity of the p(-6G) promoter-luciferase construct. pGL3 represents the blank
vector, which does not contain any AGT promoter sequence. Values are presented as means6SE.
doi:10.1371/journal.pone.0029951.g004
Figure 5. EMSA results of comparison of the binding affinities of biotinylated oligonucleotides. (A) Lanes 1 and 2 indicating the
mobilities of labeled, biotinylated oligonucleotides (A33 and G33) with nuclear extracts. A stronger shift was observed in the G33 in comparison to
the A33 oligonucleotide. Lanes 3 and 4 showing the competition experiments. The unlabeled oligonucleotides completely inhibited the specific
binding complex of biotin-labeled A33 and G33 probes to nuclear extract. (B) Lanes 1 and 2 indicating the mobilities of labeled oligonucleotides (G23
and A23) with nuclear extracts. A stronger binding complex was observed in G23 in comparison with the A23 oligonucleotide. The unlabeled
oligonucleotides completely inhibited the specific binding complex of biotin-labeled G23 and A23 probes to nuclear extract in lane 3 and 4. The
arrow points to the specific nuclear complex, which binds with the labeled, biotinylated oligonucleotides. C = competitor.
doi:10.1371/journal.pone.0029951.g005
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1573.1761599.22: 1536.0061005.51 ms, P=0.83). The results
indicated that electrophysiologic criteria for supporting SSS
diagnosis were similar among the patients with AA, AG and GG
genotypes.AlthoughtheSSSgroupshowed a increasedincidenceof
GG and AG genotypes compared with the control group (SSS
group vs. control group=43/113 (38.1%) vs. 22/125 (17.6%),
p,0.001), the severity for supporting SSS diagnosis in AG and GG
genotypes by CSRT was no less than that for the AA genotype.
Discussion
It is well-known that malfunctions in HCN-4, SCN5A, and
connexin are genetically associated with familial SSS. In addition,
sinus node fibrosis has been reported to cause abnormal sinus node
function [1]. Moreover, the risk for fibrosis-related SSS without
genetic inheritance (non-familial SSS) is known to increase with
age [1,2]. Only a few studies have analyzed the influence of
genetic characteristics on the development of fibrosis and age-
related SSS. Since the pathogenesis of non-familial SSS is quite
different from that of familial SSS, it is of interest to explore the
underlying mechanism of non-familial SSS. In the present study,
we showed that AGT promoter polymorphism is highly associated
with non-familial SSS, possibly by modulating AGT expression.
This result may provide useful information in the prevention of
age-related non-familial SSS.
RAS has been implicated in cardiac fibrosis and sinus node
dysfunction [13,14]. It has been reported that angiotensin II
mediates the proliferation of fibroblasts through the mitogen-
activated protein kinase signaling pathway [28,29]. Immunohisto-
chemical studies with monoclonal antibody against the endogenous
proteins of AGT in the heart visualized their expression in the
cardiac conduction system [11]. Autoradiography also showed that
angiotensin II bindingsites (AT1 receptors) arelocalized inthe sinus
and atrioventricular nodes of rat hearts [12]. In addition,
angiotensin II induces cardiac apoptosis via AT1 receptors in the
conducting system [29]. These studies suggest that fibrosis-related
non-familial SSS may be closely associated with alterations in RAS.
Single locus, haplotype analyses, and transcriptional
activity of AGT gene promoter polymorphisms
Although the present study showed four polymorphic sites at
positions -6, -20, -152, and -217 in the promoter region of the
AGT gene (Table 3), only the position at -6 with nucleotide
substitution GA was found to be significantly different between
control and SSS groups. In the haplotype analysis, we found 5
major haplotypes of the AGT promoter polymorphism in control
and SSS patients (Table 2). The GGAG haplotype (with a single
AG nucleotide substitution at position -6) was found to be
associated with a significant risk for SSS in comparison to the
common haplotype GGAA. In addition, compared to the control
group, the SSS group had a higher frequency of the G allele and a
lower frequency of AA genotype for the G-6A polymorphism.
Taken together, these results suggest that G-6A polymorphism is a
locus significantly associated with non-familial SSS.
The frequency of the G allele in our control Taiwan Chinese
population was 8.8%, which is lower than that reported in the
white European population (49.6%) [30]. The frequency of the
AGT G-6A AA genotype in our control population was 61.9%,
which is higher than that reported in the white European
population (28.6%) [30]. Recently, a rare polymorphic site in
MYH6 has been reported to be associated with high risk of non-
familial SSS [6]. Apparently, non-familial SSS is one of the
complex diseases associated with multiple susceptibility loci [7]
such as that different ethnic population would appear the
distinguished association pattern between genomic polymorphism
and incidence of this syndrome.
In the present study, the luciferase activity assay demonstrated
that the AGT promoter with nucleotide G at -6 had a lower
transcriptional activity in comparison to the promoter with
nucleotide A at -6 (Figure 4). Results obtained with a competitive
binding assay on 2 different lengths of the oligonucleotide
containing the specific nucleotide A or G at the -6 position of
the AGT promoter indicated that a polymorphic site at the -6
position of the AGT promoter, regardless of having a length
spanning from 23 to 33 nucleotides, would affect the binding
affinity of the specific nuclear complex that modulates basal
transcription of AGT gene expression. The EMSA result also
indicates a stronger binding affinity to nuclear protein extracts for
the oligonucleotide containing a nucleotide substitution for A to G
at position -6. Consistent with a previous study by Inoue et al.
[31], the present study strongly suggested that G-6A polymor-
phism involved in modulation of the AGT promoter activity is
responsible for the RAS-induced fibrosis found in non-familial
SSS.
In the present study, we found that the G-6A polymorphism
modulates the AGT promoter activity and significantly increases
the susceptibility for non-familial SSS. Based on the luciferase
assay, the AGT promoter containing G at -6 showed a lower
transcriptional activity than the AGT promoter containing A at -
6. Accordingly, the AA genotype was determined to be the
genotype with the highest transcription activity, the heterozygous
AG genotype has an intermediate transcriptional activity, and the
GG genotype has the lowest transcription activity. The effect of
the heterozygous AG genotype on modulating AGT promoter
activity is considered to be intermediate among the 3 genotypes.
Therefore, the effect on the susceptibility for non-familial SSS is
less with the AG genotype than with the GG genotype. In our
study population, all subjects with the GG genotype of AGT G-
6A polymorphism presented with non-familial SSS. However,
some of the AG genotype subjects were free of bradycardia with
non-familial SSS. This may be due to the intermediate
modulating effect on the AGT promoter in the heterozygous
AG genotype. In addition, non-familial SSS is considered as a
complex disease associated with multiple susceptibility loci [6,7].
Some subjects with AG genotype did not have the phenotype of
non-familial SSS. This may be due to the complex susceptibility
for SSS being determined by multiple susceptibility loci including
the G-6A polymorphism and other unknown loci; this hypothesis
should be investigated, along with the influence of environment
factors.
A recent report by Holm H et al. provided the genome-wide
association data associated with SSS [6]. Based on their results, G-
Table 4. Effects of AGT G-6A polymorphism on heart rate and
PR interval measured by ECG recordings in control patients
without SSS.
Genotypes
AG AA P
(N=22) (N=97)
Heart rate (beats/min) 68.2612.2 74.4611.9 0.03
PR interval (ms) 164.9626.5 154.1618.2 0.07
doi:10.1371/journal.pone.0029951.t004
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was not included. This might be due to the complex susceptibility
of SSS determined by multiple susceptibility loci, included ethnic
population, and age differences. In our study, for seventy-year-old
Taiwanese patients (n=113) and controls (n=125) the AGT
promoter polymorphism G-6A was found to be highly associated
with non-familial SSS (Table 2 and 3). A variant G-6A in AGT
promoter appears to be a novel determinant associated with non-
familial SSS in aged Taiwanese patients. It will be of interest to
investigate the disturbance of RAS in the aged patients
characterized with non-familial SSS in the future.
Effects of G-6A polymorphism on heart Rate and PR
interval
In addition to affecting non-familial SSS patients (Tables 2 and
3), AGT G-6A polymorphism clearly has substantial effect on
sinus node function in control patients without non-familial SSS
(Table 4). Since the patients with homozygous GG genotype
examined in this study all appeared non-familial SSS (Table 3),
heterozygous AG control patients without SSS was compared to
homozygous AA control patients for evaluating the effect of G-6A
polymorphism on the sinus rate in a population without non-
familial SSS. In this study, the heterozygous AG patients with G
allele at -6 position significantly have a 6.2 beats/min lower heart
rate and a 10.8 ms longer PR interval than the AA patients based
on the resting ECG examination (Table 4). In addition to the
results of the resting ECG, the Holter ECG results also showed a
significant trend of a lower average heart rate in the AG genotype
than in the AA genotype consistent with the results of heart rate
comparison in the resting ECG of the control group. These results
support the findings that the AGT G-6A polymorphism has effects
on sinus node function in the control subjects. In contrast to these
findings for the G-6A polymorphism on heart rate and PR
interval, we did not find an effect on heart rate and PR interval
due to the Cx 40 -44/+71 polymorphism. These results verified
the functional association of AGT G-6A polymorphism to sinus
node function and rhythmic conduction in control and non-
familial SSS patients.
Electrophysiologic study findings and G-6A genotypes
Based on the estimated CSRT from the electrophysiologic
study of the SSS patients, we found there were no significant
differences in the CSRT values among the patients with AA, AG
and GG genotypes. The results indicate that the electrophysio-
logic criteria for supporting SSS diagnosis were similar among the
patients with AA, AG and GG genotypes, but do not indicate that
the sinus node functions based on the estimated CSRT values
were similar among the AA, AG and GG genotypes. In the
present study, the electrophysiologic study was used to assist the
diagnosis of non-familial SSS and was only performed in the SSS
group. The effects of the different genotypes on the susceptibility
for SSS were demonstrated by the increased incidence of
genotypes with the G allele (AG and GG genotypes) in the SSS
group compared with the control group. We suggest that sinus
node function in AG and GG genotype should be lower than in
the AA genotype with an increased CSRT in the control subject,
which could be verified by obtaining the CSRT for the control
group. However, we did not perform this invasive procedure in
the control patients without symptoms or signs of SSS.
Nevertheless, we demonstrated the results of sinus node function
based on heart rate (sinus rate) measurements and showed that
the AG genotype has a lower sinus rate than the AA genotype
(Table 4).
Mechanism for G-6A AGT polymorphism is associated
with SSS
Cardiac pacemaker activity is regulated by different classes of
ion channels [2,5]. A recent study investigating the expression of
ion channels in the human sinus node has shown the role of
various ion channels (e.g., HCN, SCN5A, K
+ channels, and Ca
++
channels) in generating pacemaking activity [2]. Studies using
transgenic knockout animals for HCN4, Ca
++ channels, Na
+
channels, and Cx40 demonstrated that all these ion channels, as
well as gap junctions, are involved in the control of sinus node
pacemaking function [2,32]. Contrary to familial SSS, which is
due to the genetic control of ion channels, non-familial SSS is
believed to be closely associated with cardiac fibrosis occurring
during the aging process, and during which ion channels and gap
junctions may be modified by RAS disorders [12,33]. A recent
study using angiotensin converting enzyme 8/8 transgenic mice
with local overexpression in cardiac tissue showed that RAS
overexpression resulting in the downregulation of SCN5A and gap
junction proteins leads to low-voltage electrical activity and
conduction delays in the heart [34]. It appears that cardiac-
specific RAS dysregulation causing changes in SCN5A and gap
junction protein levels may be associated with non-familial SSS. In
addition, the RAS has been reported to regulate potassium
channels via the AT1 receptor in atrial myocytes derived from
guinea pig hearts [32] and acts as a modulator of L-type calcium
channels by activating protein kinase C via the AT1 receptor
[34,35]. These studies validate the novel action of RAS in
modulating ion channels and gap junctions via the AT1 receptor,
which results in a dysfunction of the pacemaking activity in the
fibrotic heart tissue.
It has been reported that overexpression of the AT1 receptor
causes sinus bradycardia [14]. Upregulation of AT1 receptors was
observedinAGTknockoutmice. Thesestudies indicate thatthereis
a feedback mechanism for the RAS and AT1 receptors in
cardiovascular homeostasis [17]. The present study consistently
shows that the SSS group, which has a higher frequency of G at
position -6, has a lower AGT transcriptional activity than the
control group. This suggests a unique feedback mechanism for the
modulation of RAS expression, which may result in sinus node
fibrosis and in the downregulation of ion channels and gap junction
proteins in the heart. To our knowledge, this is the first study to
demonstrate the association between G-6A AGT promoter
polymorphisms and non-familial SSS, and provides functional
results to clarify the underlying mechanism of non-familial SSS.
Study limitations
Based on our study results, we found that the G-6A
polymorphism is associated with non-familial SSS, and tried to
utilize functional studies, including EMSA and luciferase assay, to
explain the underlying mechanism of the candidate locus that
affects the sinus node. However, the possible feedback mechanism
of the RAS system that affects the development of non-familial
SSS via modulation of AGT gene expression by G-6A polymor-
phism still needs additional in vivo studies for further clarification.
Another limitation of the study is that the study population is
small. Our results should be confirmed in a larger scale study.
Conclusions
Patients with SSS have a lower frequency of the AGT G-6A AA
genotype and a higher G allele frequency, suggesting a possible
role for the AGT G-6A promoter polymorphism in determining
the risk of SSS. Results obtained with the EMSA assay suggested
that nucleotide substitution in AGT polymorphic site -6 would
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complex and transcription activity. Taken together, the data
reported in this study provide biological insight for the possible
mechanism of non-familial SSS. The results suggest that AGT
promoter G-6A polymorphisms act as modulators of the
transcription activity of RAS molecules, thereby contributing to
non-familial SSS.
Supporting Information
Figure S1 AGT A-20C genotyping by direct sequencing.
The arrows indicate the polymorphic sites of AA, AC and CC
genotypes.
(TIF)
Figure S2 AGT G-152A genotyping by direct sequencing.
The arrows indicate the polymorphic sites of GG and AG
genotypes.
(TIF)
Figure S3 AGT G-217A genotyping by direct sequencing.
The arrows indicate the polymorphic sites of GG, AA and AG
genotypes.
(TIF)
Figure S4 Cx40 -44/+71 polymorphism genotyping by
direct sequencing. The arrows indicate the polymorphic sites of
the different genotypes.
(TIF)
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